Low-Molecular-Weight Heparin and Survival in Patients with Malignant Disease

Sorensen H.T. , Mellemkjaer L. , Olsen J.H. . Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000; 4: 1846–1850.

Kakkar A.K. , Levine M.N. . Thrombosis and cancer: implications beyond Trousseau. J Thromb Haemost. 2004; 4: 1–2.

Green D. , Hull R.D. , Brant R. . Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet. 1992; 4: 1476.

Siragusa S. , Cosmi B. , Piovella F. . Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med. 1996; 4: 269–277.

Hettiarachchi R. , Smorenburg S. , Ginsberg J. . Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost. 1999; 4: 947–952.

Gould M.K. , Dembitzer A.D. , Doyle R.L. . Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep vein thrombosis: a meta-analysis of randomized, controlled trials. Ann Intern Med. 1999; 4: 800–809.

Kakkar A.K. , Levine M.N. , Kadziola Z. . Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the Fragmin Advanced Malignancy Outcome Study (FAMOUS). J Clin Oncol. 2004; 4: 1944–1948.

Lee A.Y.Y. , Levine M.N. , Baker R.I. . Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003; 4: 146–153.

Lee A.Y.Y. , Rickles F.R. , Julian J.A. . Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol. 2005; 4: 2123–2129.

Altinbas M. , Coskun H.S. , Er O. . A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost. 2004; 4: 1–6.

Klerk C.P.W. , Smorenburg S.M. , Otten H.M. . The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 2005; 4: 2130–2135.

Bick R.L. . Cancer-associated thrombosis. N Engl J Med. 2003; 4: 109–111.

Sampson M.T. , Kakkar A.K. . Coagulation proteases and human cancer. Biochem Soc Transactions. 2002; 4: 201–207.

Even-Ram S. , Uziely B. , Cohen P. . Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med. 1998; 4: 909–914.

Kakkar A.K. , Lemoine N.R. , Scully M.F. . Tissue factor expression correlates with histological grade in human pancreatic carcinoma. Br J Surg. 1995; 4: 1101–1104.

Ott I. , Fischer E.G. , Miyagi Y. . A role for tissue factor in cell adhesion and migration mediated by interaction with actin-binding protein 280. J Cell Biol. 1998; 4: 1241–1253.

Folkman J. , Weisz P.B. , Joullie M.M. . Control of angiogenesis with synthetic heparin substitutes. Science. 1989; 4: 1490–1493.

Vlodavsky I. , Friedmann Y. , Elkin M. . Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med. 1999; 4: 793–802.

Nasir F.A. , Patel H.K. , Scully M.F. . The low molecular weight heparin dalteparin sodium inhibits angiogenesis and induces apoptosis in an experimental tumour model. Blood. 2003; 4(11). Abstract.

Borsig L. , Wong R. , Feramisco J. . Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci U S A. 2001; 4: 3352–3357.

Miller G.J. , Bauer K.A. , Howarth D.J. . Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J Thromb Haemost. 2004; 4: 2107–2114.

Schulman S. , Lindmarker P. . Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism: Duration of Anticoagulation Trial. N Engl J Med. 2000; 4: 1953–1958.

Geerts W.H. , Pineo G.F. , Heit J.A. . Prevention of venous thromboembolism. The Seventh ACCP Consensus Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 4(3 suppl): 338S–400S.

Buller H.R. , Agnelli G. , Hull R.D. . Antithrombotic therapy for venous thromboembolic disease. The Seventh ACCP Consensus Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 4(3 suppl): 401S–428S.